



## GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference

June 1, 2018

ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 1, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference in New York, on Thursday, June 7, 2018, at 11:30 a.m. ET.

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at [www.glycomimetics.com](http://www.glycomimetics.com).

### About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271 (uproleselan), an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics is also conducting a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180601005786/en/>

Source: GlycoMimetics

GlycoMimetics, Inc.

**Investor Contact:**

Shari Annes, 650-888-0902

[sannes@annesassociates.com](mailto:sannes@annesassociates.com)

or

**Media Contact:**

Jamie Lacey-Moreira, 410-299-3310

[jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)